DOLE
20.12.2022 17:17:38 CET | Business Wire | Press release
Dole plc (NYSE: DOLE) announced today the release of its first sustainability report since the 2021 merger of Total Produce plc and Dole Food Company. Building on its historical achievements, this report sets out the organization’s refreshed sustainability framework and offers a new set of environmental, social and governance (ESG) goals through 2030.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221220005564/en/
The Dole Way, Dole’s sustainability framework, focuses on robust governance and three core pillars—For Nature, For People and For Food—covering environmental, ethical and social and nutrition related issues. These three pillars incorporate key areas identified as being most material to the impact of our business’ operations.
- For Nature: By committing to the Science Based Target Initiative, Dole plc places climate action at the forefront of its priorities along with water stewardship, biodiversity, waste management and packaging reduction and innovation.
- For People: Directly employing 38,500 people globally while partnering with third party growers worldwide, Dole is committed to being an employer of choice, supporting local communities and protecting human rights across its supply chains.
- For Food: Dole is committing to promoting healthy nutrition and improving access to fresh produce through partnerships and donations.
“Dole has built market-leading positions across a wide range of fresh fruit and vegetable segments by incorporating sustainability into their growth models,” stated Rory Byrne, Dole plc Chief Executive Officer. “As our climate is changing, we are focused on identifying the related risks, adapting to the effects on our operations and minimizing our own impacts. We also recognize and relish the special role we can play in improving people’s lives and the contribution Dole can make to promoting good health and wellbeing.”
The report also lays the foundation for the promotion of regenerative farming practices across Dole’s own operations as well as on associated farms which will support the business’ ambitious climate goals.
Highlights of the report include Dole plc’s:
- First global carbon footprint collection including measuring and managing scope 1, scope 2 and scope 3 emissions resulting in a reduction of 4% in Scope 1 and 2 emissions (2021 over 2020)
- Investment in Renewal Energy with two 2.8 megawatt wind turbines in Dole Fresh Vegetables in Soledad, California and installed new solar panel system at Belfast, Ireland site with a capacity of 120 kWp
- Recognition by American-Costa Rican Chamber of Commerce (AmCham) of Dole affiliate, Standard Fruit Company de Costa Rica S.A., for their innovative project "De la Mano con Dole." The project positively impacts the social development of employees and their families using the Business Multidimensional Poverty Index (bMPI) methodology which measures poverty beyond only per capita income - to include access to health, education, housing, work, social protection and 16 other key indicators.
Xavier Roussel, Dole plc’s Chief Marketing and Sustainability officer, stated, “Although fresh produce has a low environmental footprint in comparison to other food sources, there is still much to do to further decrease our impacts and adapt to the effects of climate change. We are addressing those challenges for the long term with likeminded partners along the supply chain. Our vertically integrated business model allows us to research much in our own operations before expanding to our associated farmers which is instrumental to lead change in the industry.”
Adding, “Caring for our most important resources: our people, the nature around us and the food we deliver to the world is our way to contribute to society and will set us up for continued success.”
To view the full Dole plc 2022 Corporate Responsibility & Sustainability Report click here or visit www.doleplc.com.
About Dole plc
A global leader in fresh produce, Dole Plc grows, markets, and distributes an extensive variety of fresh fruits and vegetables sourced locally and from around the world. Dedicated and passionate in exceeding our customers’ requirements in over 75 countries, our goal is to make the world a healthier and a more sustainable place. For more information, please visit www.doleplc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005564/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Expands ConnectAI Charter Program with Mars Snacking22.10.2026 12:45:00 CEST | Press release
Mars joins a growing group of global companies working with NIQ forward-deployed engineers to bring proprietary consumer and market intelligence into enterprise AI workflows NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced Mars as a new ConnectAI Charter client, expanding the program’s growing roster of global companies working with NIQ to build the intelligence foundation for amplifying enterprise AI workflows. Through the ConnectAI Charter Program, NIQ forward-deployed engineers and data scientists are working with Mars to embed NIQ intelligence in the expansion of AI-enabled workflows across its business. The engagement focuses on connecting NIQ data, models, and business context with Mars’ AI ecosystem to help reduce the distance between data and decision-making. Together, they are tackling use cases like conversational analytics and harmonized product data to lay the foundation for future use cases. “As we expand the use of AI across our business, we
Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer22.10.2026 12:18:00 CEST | Press release
An independent, blinded evaluation of 620 patients from the phase III PANTHER trial identified nearly one-quarter as Low Risk despite clinically high-risk breast cancer, with favorable ten-year outcomes. Spotlight Medical, a company developing AI-powered prognostic tests in oncology, today announced results from an independent evaluation of myStage Dx, its CE-IVDR-marked test for assessing recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer. The study was conducted by researchers at Karolinska Institutet in Sweden. Independent, Blinded Evaluation Using Phase III Trial Data The study used data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dxpredictions were generated blinded to clinical outcomes. Researchers at Karolinska Institutet linked the predictions to patient outcomes and independently assessed prognostic performance according to a prespecified p
Zoomtopia: Zoom lancerer nye AI-funktioner22.10.2026 12:13:00 CEST | Pressemeddelelse
Zoom vil forkorte vejen fra mødebeslutning til udført arbejde. På konferencen Zoomtopia præsenterer virksomheden Unified Context Layer – et fælles informationslag, der forbinder samtaler, dokumenter og data, så AI kan forstå sammenhængen og hjælpe med de næste skridt. Samtidig lanceres flere nye AI-produkter og -funktioner, der skal gøre det lettere at omsætte diskussioner og beslutninger til handling. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261021318859/da/ I møder og samtaler træffes vigtige beslutninger, og virksomheder får værdifuld indsigt i deres kunder. En kundedialog kan begynde i et møde, fortsætte i telefonen og derefter gå over i en chat. Når informationen spredes mellem forskellige værktøjer, bliver det svært for både medarbejdere og AI-agenter at få et samlet billede af, hvad der er blevet sagt og besluttet. Resultatet er, at værdifuld tid går med at finde ud af, hvad der er blevet sagt og besluttet, og
TACTICAAI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 12:01:00 CEST | Press release
Collaboration brings together TACTICAAI’s operational decision-intelligence technology and NVIDIA AI capabilities to advance reasoning, autonomous analysis and video intelligence for real-world deployment TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
